High Levels of Anti-Cyclic Citrullinated Peptide Autoantibodies Are Associated with Co-occurrence of Pulmonary Diseases with Rheumatoid Arthritis

Objective. To investigate whether levels of anti-cyclic citrullinated peptide antibodies (anti-CCP2) in patients with rheumatoid arthritis (RA) are associated with the co-occurrence of lung diseases. Methods. A total of 252 RA patients were included in a cross-sectional study. Pulmonary disease was confirmed by high-resolution chest computed tomography scan. Circulating anti-CCP2 were quantified using ELISA. Multivariate logistic regression was conducted to identify independent risk factors for lung disease. Results. Male sex (OR 3.29, 95% CI 1.59–6.80) and high anti-CCP2 levels (OR 1.49, 95% CI 1.25–1.78) were identified as independent risk factors for lung disease in the RA population. Conclusion. High anti-CCP2 levels are associated with lung disease in the RA population.

[1]  Cynthia S Crowson,et al.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. , 2010, Arthritis and rheumatism.

[2]  Hiroshi Watanabe,et al.  Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. , 2008, Clinical biochemistry.

[3]  L. Alfredsson,et al.  Immunity to citrullinated proteins in rheumatoid arthritis. , 2008, Annual review of immunology.

[4]  K. Theodoridou,et al.  Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis , 2008, Clinical Rheumatology.

[5]  F. Breedveld,et al.  Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. , 2006, Arthritis and rheumatism.

[6]  M. Gaxiola,et al.  Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. , 2006, The Journal of clinical investigation.

[7]  Y. Akgün,et al.  Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. , 2006, Clinical biochemistry.

[8]  D. Lynch,et al.  Rheumatoid arthritis-related lung diseases: CT findings. , 2004, Radiology.

[9]  S. Gabriel,et al.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years , 2003, Annals of the rheumatic diseases.

[10]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[11]  D. Schwartz,et al.  Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. , 1996, Arthritis and rheumatism.

[12]  P. Corris,et al.  Bronchus associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non-smokers. , 1993, Thorax.

[13]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[14]  L. Alfredsson,et al.  A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. , 2006, Arthritis and rheumatism.